secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001628280-26-021189
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026
--------------------------------------------------------------------------------

- Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.
- Cash, equivalents and marketable securities $116.9M as of Dec 31, 2025; expected to fund operations into early 2027.
- Phase 2 ALTITUDE-AD (sabirnetug) topline results expected late 2026; OLE dosing commenced Nov 2025.
- $35.75M private placement closed March 2026 to advance Enhanced Brain Delivery (EBD) program; IND filing targeted mid-2027.
- EBD program candidates showed up to 40-fold brain exposure in NHPs; low anemia risk; subcutaneous potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/0001628280-26-021189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-021189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer